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ABSTRACT
Disruption of Epstein - Barr virus (EBV) latency is
mediated through the activation of the viral immediate-
early proteins, BZLF1 (Z) and BRLF1 (R).i.; (Chevallier-
Greco, A., et al., (1986) EMBO J., 5, 3243-9;
Countryman, and Miller, G. (1985) Proc. Nati. Acad. Sci.
USA, 82, 4085-4089). We have previously
demonstrated that these proteins cooperatively activate
the EBV early promoter BMRF1 in lymphoid cells but
not in epithelial cells. Although cooperative
transactivation by these proteins has been
demonstrated with a number of EBV promoters, the
mechanism of this interaction is not well understood.
We now show that the cooperative activation of the
BMRF1 promoter by Z-plus-R requires an intact R
binding site and at least one functional Z response
element (ZRE). Despite the presence of an R binding
site, the BMRF1 promoter is only moderately
responsive to R alone in either HeLa or Jurkat cells.
Efficient activation of the BMRF1 promoter by Z alone
in HeLa cells requires two ZREs (located at - 59 and
- 106), whereas two additional Z binding sites (located
at - 42 and - 170) contribute very little to Z-induced
activation. In the absence of ZREs, Z acted as a
repressor of R-induced transactivation. These
observations, along with observations made by other
investigators (Giot, J.F. et a/., (1991) Nucleic Acids
Res., 19, 1251 - 8), suggest that Z-plus-R cooperative
activation is dependent upon 1) direct binding by R and
Z to responsive promoter elements and 2) contributions
by cell-specific factors.
INTRODUCTION
Epstein-Barr virus (EBV) produces either a latent
(predominantly in B cells) or lytic (predominantly in epithelial
cells) infection (1, 2). Overexpression of the immediate-early
BZLF1 transactivator (Z) is sufficient for reactivation of EBV
infection from latency (3-10), indicating that Z plays a key role
in EBV regulation. Z-induced activation is mediated by direct
binding of the Z homodimer to specific DNA sequence motifs,
including consensus AP-1 and C/EBP sites as well as Z response
elements (ZREs) (11-17). A second EBV immediate-early
protein, BRLF1 (R), (18) is translated from a bicistronic mRNA
which also encodes Z (19). Consistent with the notion that R and
Z have cooperative functions during viral reactivation in vivo,
several EBV early promoters have been shown to be
cooperatively activated by R and Z in transient expression assays
(13, 20, 21, 25). R has recently been reported to be a sequence-
specific DNA-binding protein (21-24). However, at present only
one laboratory has been able to demonstrate R DNA binding
activity (23) and very little is known about the characteristics
of the R response elements. The importance of binding by R in
Z-plus-R cooperative activation of responsive promoters has not
been well studied.
We have previously found that R and Z interact cooperatively
to activate the early BMRF1 promoter in lymphoid cells but not
in epithelial cells and that the cooperative effect of Z-plus-R
occurs at the level of BMRFl-directed transcription (25). We
have shown that the Z protein binds to a consensus AP-1 site
in the BMRF1 promoter (26), but other potential Z or R binding
sites in the BMRF1 promoter have not been previously studied.
In this paper, we describe experiments which extend our
previous work on the regulation of the BMRF1 promoter by Z
and R. We demonstrate that transactivation of the BMRF1
promoter by Z in HeLa cells is mediated by direct Z binding
to the AP-l site and an additional upstream Z response element.
We show that the R transactivator also binds directly to the
BMRF1 promoter and that both the R binding site and one of
the functional ZREs are required for efficient Z-plus-R activation.
In addition, we demonstrate that Z can function as either an
enhancer or repressor of R-induced transactivation depending
upon the presence or absence of functional Z binding sites. These
results are in agreement with recent findings by another laboratory
using artificial promoter constructs (21) and suggest that
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cooperative transactivation of the BMRF1 promoter by the Z-
plus-R combination is mediated by direct binding by both the
Z and R transactivators to responsive promoter elements. The
increased activation which is seen when both R and Z bind to
this promoter could result directly from the cooperative effects
of the Z and R transactivator domains (27). However the finding
that cooperative activation of BMRF1 promoter does not occur
in epithelial cells suggests that cellular factors must contribute
to Z-plus-R cooperative activation.
MATERIALS AND METHODS
Cell lines
Jurkat, a T-cell line, was maintained in RPMI 1640 medium;
HeLa, a cervical epithelial cell line, was maintained in Dulbecco
modified Eagle medium H. Both were supplemented with 10%
fetal calf serum.
DNA transfections
Plasmid DNA was purified through two sequential cesium
chloride gradients. DNA was transfected into both lymphoid and
epithelial cell lines by electroporation (28). For each condition,
107 cells were shocked at 1,500 V with the Zapper
electroporation unit (Medical Electronics Shop, University of
Wisconsin). Epithelial cells were harvested and resuspended into
RPMI medium for electroporation.
Plasmids
The plasmid pEA-BS-CAT was made by inserting the
XbaI-BamHI fragment of pEA-CAT (which contains the
complete BMRF1 promoter sequences, 79,537 to 79,898, the
CAT gene and the SV40 polyadenylation site) into the
XbaI-BamHI site of the M13 Bluescript SK+ plasmid
(Stratagene), as previously reported (25). The pEBV-ZIE plasmid
contains the BamHI Z gene fragment (EBV nucleotides 101,741
to 103,947) in the pGEM2-based vector pHD1013 (29), such
that the BZLF1 gene is under the control of the strong human
cytomegalovirus (CMV) immediate-arly promoter. In the pEBV-
RIE plasmid, a HindIII -HindIJl fragment from pEBV-RZ (which
contains EBV nucleotides 103,080 to 105,412 linked to the CMV
promoter) (25) was ligated into the pUC18 vector.
CAT assays
Cells were transfected with 10 Aig of plasmid DNA (5 jig
transactivator and S jig reporter construct) as described above.
At 48 hours after transfection, a cell extract was prepared and
incubated at 370 C with 14C chloramphenicol in the presence of
acetyl coenzyme A as described previously (30). The percent
acetylation of chloramphenicol was quantitated by thin layer
chromatography followed by scanning of the chromatography
plates by an AMBIS scanner (AMBIS, Inc.) for 10 hours. If
results were not in the linear range, CAT assays were repeated
with less extract.
In vitro site-directed mutagenesis
Mutants were made by using the BIO-Rad Muta-Gene phagemid
in vitro mutagenesis kit, based on a method described by Kunkel
et al. (31). Synthetic oligonucleotides were complementary to
the region to be altered except for a limited internal mismatch.
For screening possible mutants, synthetic oligonucleotides were
created such that in vitro mutations would create a new PvuII
or XbaI restriction site allowing each possible mutant to be
analyzed by digestion with restriction endonucleases. Following
initial screening, potential mutants were sequenced with the
Sequenase 2.0 enzyme sequencing kit (United States Biochemical
Corp.). Single stranded oligomers used for constructing site-
directed mutants are listed below. Mutated sequences within the








The in vitro translated BZLF 1 protein was expressed from an
SP64 vector containing an 870-base-pair cDNA for BZLF1 (gift
of P.Farrell, (11)). The plasmid was digested with EcoRI and
transcribed using SP6 polymerase (Promega). The RNA obtained
was used to program protein synthesis using wheat germ extract
(Promega). Correct translation was confirmed using 35S-
methionine-labeled protein analyzed by SDS -PAGE and
autoradiography.
A Z/glutathione S-transferase fusion protein (GST-Z) was
created by removing the Z cDNA from the SP64 construct (gift
of P.Farrell, (11)) with the restriction enzymes BamHI and
EcoRI, filling in all 5' protruding ends with Klenow DNA
polymerase and ligating to the SnaI site of the glutathione S-
transferase (GST) vector, pGEX-3X. This put the BZLF1
sequence in frame, and downstream, of the glutathione S-
transferase carrier protein to create the plasmid pGST-Z. In the
E. coli host DH5azF', these plasmids were induced for 4 hours
at 30°C with 1 mM IPTG. Bacteria were lysed in 50 mM KCl,
8 jiM leupeptin and 0.5 mM PMSF by sonication, and cleared
by centrifugation. Lysates were assayed for protein concentration
by the Bradford method (32), then used directly in gel retardation
assays.
R protein expression
Using the polymerase chain reaction (PCR) with Vent polymerase
(New England Biolabs), an EcoRI site was created just 5' to the
BRLF 1 initiation codon. An EcoRI to ApaI fragment of the PCR
product, containing the first 356 codons of the BRLF1 reading
frame, was ligated blunt end into the EcoRI site of the pGEX-3X
expression vector (Pharmacia) by first filling in all 5' protruding
ends with Klenow DNA polymerase. This put the BRLF1
sequence in frame, and downstream, of the glutathione S-
transferase carrier protein to create the plasmid pGR356 encoding
the GST carrier protein fused to the first 356 amino acids of R
(GR356). The negative control vector, pGR-, contains the
BRLF1 reading frame in an antisense orientation with respect
to glutathione S-transferase. In the E.coli host DH5aF', these
plasmids were induced for 4 hours at 30°C with 1 mM IPTG.
Bacteria were lysed in 50 mM KCl, 8 jIM leupeptin and 0.5 mM
PMSF by sonication, and cleared by centrifugation. Lysates were
assayed for protein concentration by the Bradford method (32),
then used directly in gel retardation assays.
Gel retardation assays
DNA binding reactions were performed as described previously
(11, 23) with the following modifications. 32P-labeled probes
were constructed by isolating restriction fragments of the BMRF1
promoter. 5 ,il of in vitro translated Z protein, 5Ag of GST-Z
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fusion protein or GR356 fusion protein (or equal amounts of the
corresponding negative control) were incubated with 2 x 104
cpm of 32P-labeled probes for 30 minutes at room temperature.
The Z binding reactions were performed in 20 1l of 100 mM
KCl, 20 mM HEPES (pH 7.3), 10% glycerol, 0.2 mM EDTA,
4 mM dithiothreitol, 0.50 mM PMSF with 2 ,tg of
poly(dIdC . dIdC). The R binding reactions were performed in
30,^1 of 130 mM KCl, 10 mM HEPES (pH 7.3), 5% Ficoll,
5 mM MgCl2, 0.5 mM dithiothreitol, 0.5 mM PMSF with 1 ,ug
of poly (dIdC dIdC) at 4°C. The retarded complexes were
detected by loading the entire sample onto a 5% polyacrylamide
gel, run in 0.5% TBE buffer and detected by autoradiography.
The synthetic double-stranded oligonucleotides used in binding
reactions are listed below. Mutated sequences within the
oligomers are indicated by underlining.




AP-1 (EBV 79,801-79,821): ACCTTTGAGTCAGGGTGGCTA








































Figure 1. Identification of Z binding sites within the BMRF1 promoter. A. 32-
labeled probe containing BMRF1 sequences from -79 to -265 was incubated
with in vitro translated Z protein and then treated with dimethylsulfate immediately
prior to gel electrophoresis. The bands representing bound (B) and free (F) probe
were removed separately, cut with piperidine, and analyzed on an 8%
polyacrylamide sequencing gel. The sequence in the region of protection is shown.
Areas of protection are indicated (0, *) and an area of hypermethylation is indicated
(-). B. Probe containing the BMRF1 sequences from -79 to + 125. C. Gel
retardation assay performed with GST-Z fusion protein and a probe spanning
the -265 to -79 region of the wildtype BMRF1 promoter. The protein and the
double-stranded oligomer spanning the -153 to -187 region of the BMRF1
promoter used as competitor DNA at 1000 molar excess are indicated above each
lane. (GST: glutathione S-transferase protein; Z: GST-Z fusion protein; WT:
wildtype RRE-BMRF1 oligomer; A-158: BMRF1A-158 oligomer; A-170:
BMRF1IA-170 oligomer; A-182: BMRF1A-182 oligomer.)
RRE-ADR (EBV 53,524-53,552): TGGGAATTCCCTGTGCCTTGTCCCGTG-
TCAAATCAACCCCGGGTCC
RRE-BMRF1 (EBV 79,683-79,717): GATCGCTCCCTTGTATGGCACAC-
CACCCCCCAAGGACTGGATC
BMRF1A-158 (EBV 79,683-79,717): GATCGCTCCCTTGTATGGCACA-
CCACCCCCCATCTAGAGGATC
BMRF1l-170 (EBV 79,683-79,717): GATCGCTCCCTrGTATGGTCTAGA-
ACCCCCCAAGGACTGGATC
BMRF1A- 182 (EBV 79,683 -79,717): GATCTCTAGATTGTATGGCACA-
CCACCCCCCAAGGACTGGATC
Methylation interference and protection assays
Methylation interference was performed as previously described
(33). 1 x 105 cpm of methylated probe was incubated with 10
Ag of GR356 fusion protein in two volumes of the binding
reaction mixture used for gel retardation assays described above.
The bound and free species were excised from a 5 %
polyacrylamide gel and electroeluted onto DEAE membrane
paper (Schleicher and Schuell). The membrane was incubated
with IM piperidine at 90°C for 15-30 minutes, then rinsed twice
with 1 ml of sterile water. The probe fragments were then eluted
by incubating the membrane in 250 ul of 1 M NaCl, 0.1mM
EDTA and 20 mM Tris (pH 8) at 670 C twice and ethanol
precipitated. Dried samples were resuspended in formamide
buffer, loaded onto either a 6% or a 8% polyacrylamide-7M urea
sequencing gel and visualized by autoradiography. Methylation
protection was performed by modifying the methylation
interference procedure. Unmethylated probe was incubated with
10 dl of in vitro translated Z protein or 10 Ag GR356 fusion
protein in two volumes of binding reaction mixture. 1 1d of
dimethylsulfate was added to the binding reaction immediately
prior to loading onto a 5% polyacrylamide, 0.5% TBE gel.
Isolation of the bound and free complexes, cleavage with
piperidine and elution of the probe fragments were performed
as described above.
RESULTS
We have previously shown that the BMRF1 promoter responds
to the Z transactivator alone in HeLa cells and to the R and Z
transactivators cooperatively in Jurkat cells (25). We have also
shown that the Z-induced activation of the BMRF1 promoter is
mediated by direct binding to the consensus AP-1 site (26). In
this study we extended our examination of Z binding to the
BMRF1 promoter and explored the role ofR and Z binding sites
in activation of the BMRF1 promoter by R and Z.
Z response elements
To identify other potential Z binding sites in the BMRF1
promoter, we performed methylation protection assays (33) using
in vitro translated Z protein. A methylation protection experiment
(Fig. IA) using a probe containing the -265 to -79 region of
the BMRF1 promoter showed protection of the guanosine at
-106 (EBV 79,764). The sequence in this region is TTGCTCA
which is homologous to a previously described Z binding site
(ZRE2) in the BHLF1 promoter (15). Weak protection was also
seen at -128, -131, and -135. This sequence bears no clear
homology to previously described Z binding sites.
Using a probe (Fig. 1B) containing the region -79 to + 125
of the BMRF1 promoter, we observed protection over the AP- 1
site as previously reported (26). Additionally, in some
experiments we observed protection at residues -42 and -44.
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The sequence in this region, TGAGCAA, is a one basepair
mismatch of both the ZHIA site in the BZLF1 promoter (12,
17) and the ZRE5 site in the BHLF1 promoter (15). Taylor et
al. have reported that an oligomer containing the TGAGCAA
sequence bound Z efficiently in a gel retardation assay (17).
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Figu 2 A. Map of the BMRF1 promoter. The Z binding sites of the BMRF1
promoter are shown. B. Construction ofpEA-BS-CAT ZRE site-dircted mutants.
The parent construct, pEA-BS-CAT, contains the EBV BamHI-RsaI fragment
linked to CAT in a phagemid vector (25). The Z binding sites were abolished
using the Kunkel method (31) of site-directed mutagenesis as shown.
An additional Z binding site was found during our studies on
R binding with the BMRF1 promoter. This site was too weak
to be identified by methylation protection but it was able to bind
to Z in a gel retardation assay (Fig. IC). This site was defined
by using as competitors a series of double-stranded mutant
oligomers which span the -187 to - 153 region of the BMRF1
promoter. The oligomer containing a mutation which disrupted
the sequence TGGCACA (A -170) was no longer able to
compete successfully for Z binding (Fig. IC, Lane 5). This site
is a one basepair mismatch with the ZHIA site in the Z promoter
(17) as well as a number of other Z binding sites (13, 15).
The functional importance of the four Z binding sites in the
BMRF1 promoter was defined by cotransfection and
chloramphenicol acetyltransferase (CAT) (28, 30) assays in HeLa
and Jurkat cells. Using the method of Kunkel et al. (31), we
constructed mutations abolishing the -170 site, -106 site, the
AP-1 site (25), the -42 site or the -106 and AP-1 sites together
(Fig. 2). In HeLa cells, where Z alone is sufficient to induce
maximal transactivation of the BMRF1 promoter (25), deletion
of either the -106 site or the AP-1 site significantly decreased
Z responsiveness (Fig. 3A). Only 13% of the Z-induced activity
of the intact BMRF1 promoter was observed after removing the
upstream binding site and only 9% of the activity of the intact
BMRF1 promoter was seen after removing the AP-1 site. When
both sites were removed (AAP1/- 106), Z response was further
decreased to 3% of the wildtype promoter. Mutation of the -42
site (A-42) or the -170 site (A-170) had no effect on Z



































Figure 3A. The BMRF1 promoter requires two Z binding sites for Z activation in HeLa cells. The BMRF1 promoter constructs (Fig. 2B) pEA-BS-CAT (wildtype),
pEA-AM06 (A-106), pEA-AAP-l-CAT (AAP1), pEA-AAP1/106 (AAP1/-106) pEA-A42 (A-42), or pEA-A170 (A-170) were cotransfected with pEBV-ZIE
(Z) into HeLa cells. The results are presented as average percent of the activity of the various promoter constructs plus Z versus the intact promoter (wildtype)
plus Z from two or three separate experiments. The upper range of the experiments is indicated by the bar above the columns. B. The Z and R transactivators
do not cooperatively activate the BMRF1 promoter in HeLa cells. The BMRF1 promoter constructs pEA-BS-CAT (wildtype), or pEA-AAPl/106 (AAPI/- 106)
were cotransfected with pHD1013 (C), pEBV-ZIE (Z), pEBV-RIE (R) or both pEBV-ZIE and pEBV-RIE (Z&R) into HeLa cells. The results are presented as
average percent acetylation of two experiments (indicated in the ordinate). The numbers above the bars indicate the average fold induction by the transactivator
versus the control plasmid.
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Z binding sites (- 106 and AP-1) appear to be functional ZREs
and both are required for efficient Z transactivation. After
destruction of both the - 106 and AP-1 sites, R remained unable
to function cooperatively with Z in this cell type (Fig. 3B).
The importance of each Z binding site was also determined
in Jurkat cells, where maximal activation of the BMRF1 promoter
requires the combination of Z-plus-R (25) (Fig. 4). Loss of either
the AP-1 site alone or the upstream -106 site alone did not
abolish the ability of the BMRF1 promoter to respond to the Z-
plus-R combination. However, deletion of either ZRE increased
the constitutive activity of the BMRF1 promoter, resulting in a
reduction in the fold-increase produced by the Z-plus-R
combination. This increase in constitutive activity was particularly
striking when both the -106 and AP-1 sites were deleted
simultaneously. Destruction of the -42 site had only a minimal
effect on Z-plus-R activation. The effects of destroying the - 170
site are shown in Fig. 9. This mutation disrupts Z-plus-R
cooperative activation but as we show below it also disrupts an
R binding site. Thus it appears that only the AP-1 and -106
sites actually function as ZREs.
When both ZREs were abolished (AAP1/- 106), the BMRF1
promoter no longer responded to the Z-plus-R combination. Of
note, however, was the finding that R alone transactivated the
double mutant approximately 4-fold, compared to the 0.7 fold
effect induced by Z and R together. Thus, in the absence of
ZREs, Z appeared to inhibit the moderate R-induced activation
of the BMRF1 promoter.
R response elements
To determine whether the cooperative effect of Z-plus-R on
BMRF1 promoter activity might also be mediated by direct R











transferase fusion protein (GR356) for protein binding studies.
The R protein has been shown to bind as a homodimer to three
sites which consist of two contact regions separated by 6-8
nucleotides (22, 23). We constructed a probe spanning the
BMRF1 promoter from -265 to + 1. We were able to
demonstrate R binding to the BMRF1 promoter (Fig. 5) which
was specifically competed by oligomers containing known R
binding sites from the EBV early DR and BMLF1 promoters
(Fig. 5, Lanes 3, 5) (22, 23) but not by oligomers containing
a mutated DR promoter R binding site or c-myb binding sites
(Fig. 5, Lane 4, 6) (26).
To identify precisely where R bound to the BMRF1 promoter,
we performed methylation protection and interference assays
using the GR356 fusion protein. A methylation protection
experiment (Fig. 6A), using a probe labeled on the coding strand
and containing the -265 to + 1 region of the BMRF1 promoter,
showed definite protection of the guanosine at -158 and possibly
at - 157 (EBV 79,712 and 79,713). The sequence in this region,
AGGAC, shows homology (4/5 basepair match) to the GGGAC
half of the DR-2 R binding site in the DR promoter (23). An
extra band does appear in the lane containing the bound probe
which may represent a hypermethylated adenosine residue at
-156.
Using a probe (Fig. 6B) containing the region -265 to -79
of the BMRF1 promoter and labeled on the noncoding strand,
we observed strong protection of the guanosines at - 173, - 171,
- 169, - 168, and - 155 and weak protection of the region from
- 166 to -161 in a methylation interference assay. The sequence
in the region - 155 to -171 (GTCCT tggggg GTGGTGI) is a
one basepair mismatch of the DR-2 R binding site and includes
the protected region on the opposite strand (Fig. 7). In addition,
there was questionable protection in the -182 region. The
Figure 4. Z-plus-R transactivation of the BMRF1 promoter in Jurkat cells requires at least one ZRE. The CAT constructs pBS-CAT (vector without BMRF1 promoter),
pEA-BS-CAT (wildtype), pEA-A106 (A-106), pEA-AAPI-CAT (AAPl), pEA-AAP1/106 (AAP1/-106) or pEA-A42 (A-42) were cotransfected with a control
plasmid (pHD1O13, C), pEBV-ZIE (Z), pEBV-RIE (R), or both (Z&R) into Jurkat cells. The results are presented as average percent acetylation of either one
(vector), two (A -42), or three (all others) experiments (indicated in the ordinate). The numbers above the bars indicate the average fold induction by the transactivator
versus the control plasmid. The average fold induction was calculated by averaging the fold induction of each individual experiment.





Figure 5. A bacterial R fusion protein binds to the BMRF1 promoter. A gel
retardation assay was performed using a bacterial R fusion protein (GR356, R)
and a probe spanning the BMRF1 promoter from -265 to + 1 relative to the
mRNA start site. The protein and the double-stranded oligomer used as competitor
DNA at 1000 molar excess are indicated above each lane. (GR-: fusion protein
constructed with R in the antisense orientation; R: GR356 fusion protein; RRE-
DR: oligomer containing a DR promoter R binding site; RRE-ADR: oligomer
containing a mutation in the DR promoter R binding site; RRE-BMLF1: oligomer
containing the BMLF1 promoter R binding site; MYBRE4: oligomer containing
four c-myb binding sites.)
sequence in this area (- 186 to -171) contains limited homology
with the DR-I site (8/11 basepair match with an interval of six
basepairs instead of seven, see Fig. 7).
Further definition of the R binding site(s) was accomplished
using gel retardation assays. Again we used the method of Kunkel
et al. (31) to construct mutants disrupting the - 182, the - 170
or the - 158 regions (Fig. 7). Probes spanning the -265 to -79
region were made from the wildtype, the A - 182, Ai- 170, and
A - 158 BMRF1 promoter constructs. Both the A - 158 and the
A -170 constructs failed to bind R (Fig. 8A, Lanes 8, 10)
whereas the wildtype and the A - 182 constructs were able to
bind to the GR356 fusion protein (Fig. 8A, Lanes 2, 12). These
results were confirmed with a competition study in which double-
stranded oligomers containing the wildtype sequence or the three
mutant sequences were used as competitors. The wildtype and
the A - 182 mutant oligomers were able to disrupt R binding
(Fig. 8A Lane 5 and Fig. 8B Lanes 3, 6) but the A-158 and
the A -170 mutant oligomers were not able to disrupt the
R/BMRF1 complex (Fig. 8B Lanes 4, 5).
The functional importance of these sites of protection was
defined by using cotransfection and CAT assays in Jurkat cells.
In Jurkat cells, where R functions cooperatively with Z to produce
activation of the BMRF1 promoter, destruction of the - 158
region (a mutation which disrupts R binding) reduced the level
of Z-plus-R activation to 30% of that seen with the wildtype
promoter (Fig. 9). Destruction of the -170 region (a mutation
which disrupts both R and Z binding to this region) reduced the
efficiency of Z-plus-R activation only slightly more efficiently.
The -182 mutant reduced Z-plus-R activation of the BMRF1
promoter to 65% of that seen with the wildtype promoter, a
reduction of questionable significance. Thus, an R binding site
is located in the BMRF1 promoter spanning the -170 and - 158
regions (Fig. 10) and this binding site is important for Z-plus-
R-induced activation.
Figure 6. Mapping of the R binding sites in the BMRF1 promoter. A. A 32-p-
labeled probe containing BMRF1 sequences from -265 to + 1 (coding strand)
was incubated with GR356 fusion protein and then treated with dimethylsulfate
immediately prior to gel electrophoresis. The bands representing bound (B) and
free (F) probe were removed separately, cut with piperidine, and analyzed on
an 8% polyacrylamide sequencing gel. The sequence in the region of protection
is shown. Areas of protection are indicated (0, *). B. A methylated 32-P-labeled
probe containing BMRF1 sequences from -265 to -79 (noncoding strand) was
incubated with GR356 fusion protein. The sequence in the region of protection
is shown. Areas of protection are indicated (0, *).
DISCUSSION
Although a number of EBV promoters are cooperatively activated
by the Z-plus-R combination, the function of Z and R binding
sites in this interaction has not been carefully analyzed. In this
study, we have dissected the role of Z and R binding sites in
the BMRF1 promoter in regard to activation by Z versus the
combination of Z-plus-R. We have identified two Z binding sites
which function as ZREs. The presence of these two elements
was shown to be critical for Z-induced activation in HeLa cells,
whereas either ZRE alone conferred Z-plus-R responsiveness in
Jurkat cells. R was also shown to bind to the BMRF 1 promoter
and destruction of the R binding site reduced the Z-plus-R effect.
Therefore, the cooperative transactivation of the BMRF1
promoter by the Z-plus-R combination in Jurkat cells appears
to be mediated by direct binding of both the Z and R
transactivators.
In HeLa cells, Z is able to transactivate the BMRF1 promoter
independently, and we have demonstrated that both the - 106
and AP-1 (-59) Z binding sites are required for Z-induced
activation. Carey et al. have recently shown that the presence
of multiple Z binding sites within a promoter contributes to
cooperative activation by Z of the promoter by a mechanism not
involving cooperative binding (34). Therefore, the requirement
for both proximal and distal Z binding sites in HeLa cells is
unlikely to reflect cooperative binding but may be due to the
ability of the transactivator domains of Z bound at proximal and
distal sites to interact cooperatively. In Jurkat cells, the Z
-_ fj-
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pEA-BS-CAT rTCDGAGGGAACATAC CGITGGT GGGGGGT ICCTGACGGG
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Figure 7. Construction of BMRF1 RRE site-directed mutants. * indicates a
protected guanine residue, ! indicates a weakly protected guanine residue. Regions
of homology with other R binding sites are indicated by brackets on the parent
construct, pEA-BS-CAT, which contains the EBV BamHI-RsaI fragment linked
to CAT in a phagemid vector (25). Three regions (underlined) were abolished
using the Kunkel method (31) of site-directed mutagenesis as shown. The new
sequences of the mutant constructs are shown below the corresponding region
of the parent construct.
transactivator alone cannot efficiently activate the BMRF1
promoter, but the combination of Z and R together produces a
striking degree of activation (25). The presence of either ZRE
alone was sufficient for cooperative transactivation by the Z-plus-
R combination in Jurkat cells. Thus, our findings suggest that
the mechanism of Z-induced transactivation of early EBV
promoters may vary from one cell type to another.
Two additional weak Z binding sites were identified which did
not contribute to Z responsiveness of the BMRF1 promoter in
HeLa cells or Z-plus-R responsiveness in Jurkat cells. These sites
may play a role in Z-induced activation in another, as yet
unidentified, context. Additionally, there may still be unidentified
Z binding sites in the BMRF1 promoter with reduced binding
affinity making identification of these sites very difficult.
The R protein was only recently shown to be a sequence-
specific DNA-binding protein. At present only three R binding
sites have been identified, two within the DR promoter and one
within the early BMLF1 promoter (Fig. 10) (21-24). The
previously identified R binding sites have consisted of two distinct
regions separated by 6-8 bases. Although all of the R sites are
GC-rich, each of the three sites have unique sequences. The
Figure 8. The BMRF1 sequence from -154 to -174 is required for R binding.
A. A gel retardation assay with probes containing mutations in the R binding
region of the BMRF1 promoter. Gel retardation assay was performed with the
GR356 fusion protein and wildtype versus mutant BMRF1 probes spanning the
-265 to -79 region. Mutant probes were isolated from the constructs shown
in Fig. 7. Probes are indicated below each lane. The protein and the double-
stranded oligomer used as competitor DNA at 1000 molar excess are indicated
above each lane. (GR-: fusion protein constructed with R in the antisense
orientation; R: GR356 fusion protein; RRE-BMLF1: oligomer containing a
BMLF1 promoter R binding site; AP-1: oligomer containing the AP-1 site in
the BMRF1 promoter; RRE-BMRF1; oligomer containing the BMRF1 promoter
region -153 to -187; MYBRp: oligomer containing four c-nyb binding sites).
B. Competition gel retardation assay with oligomers containing mutations in the
R binding region of the BMRF1 promoter. A gel retardation assay was performed
with GR356 fusion protein and a probe spanning the -265 to -79 region of
the wildtype BMRF1 promoter. The protein and the double-stranded oligomer
spanning the -153 to -187 region of the BMRF1 promoter used as competitor
DNA at 1000 molar excess are indicated above each lane. (GR-: fusion protein
constructed with R in the antisense orientation; R: GR356 fusion protein; WT:
wildtype RRE-BMRF1 oligomer; A- 158: BMRF1A- 158 oligomer; A- 170:
BMRF1A- 170 oligomer; A- 182: BMRFIA- 182 oligomer.)
sequence in the region of the BMRF1 promoter bound by R
shows a site which is very similar to the DR-2 R binding site
located within the DR promoter. Given that R was shown in this
study to bind directly to the BMRF1 promoter, it is perhaps
surprising that R alone induces only a modest degree of activation
of this promoter compared to the effect of R upon the BMLF1
and DR promoters (13, 36). DR promoter sequences other than
the actual R binding sites have been shown to influence the ability
of R to activate the DR promoter (13). Therefore, it is possible
that the location of the R binding site in the BMRF1 promoter
is not favorable for R activation due to the proximity of a binding
site for a cellular repressor of R activation or R binding.
Although we demonstrate that the -170 and -158 mutants
can no longer bind R, these mutations retain a moderate level
of R-induced activation (Fig. 9). We have observed previously
that R-induced transactivation may be mediated by more than
one mechanism (37) and we have shown recently that the EBV
BRLF1 promoter is moderately responsive to R in transfection
studies although R does not bind directly to this promoter (38).
Therefore it is quite possible that the R-induced activation of the
BMRF1 promoter which persists after removal of the R binding
site results from a nonbinding mechanism of activation.
We have recentdy reported that the cellular transcription factor
c-nyb, like R, induces cooperative transactivation of the BMRF1
promoter with Z in Jurkat cells but not HeLa cells. Unlike R,
c-nyb does not bind directly to the BMRF1 promoter (26). The
sequences surrounding the AP-1 site are sufficient to transfer Z-
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Figure 9. The R binding site is required for efficient Z-plus-R activation of the BMRF1 promoter in Jurkat cells. The CAT constructs pEA-BS-CAT (wildtype),
pEA-A158 (A- 158), pEA-A170 (A- 170), or pEA-A182 (A- 182) were cotransfected with a control plasmid (1111, pHD1013, C), pEBV-RIE (EC, R), pEBV-ZIE
(K, Z), or both pEBV-ZIE and pEBV-RIE (U, Z&R) into Jurkat cells. The results are presented as average fold activation of a minimum of seven experiments
(indicated in the ordinate). The numbers above the bars indicate the average fold activation by the transactivator versus the control plasmid. The bracketed numbers
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Figure 10. Comparison of R binding sites. Numbers above the sequences indicate
the region of the promoter in which the site is found. Numbers at the left indicate
the region of the EBV genome in which these sites can be found.
plus-c-myb responsiveness to a heterologous promoter (26) but
are not sufficient to transfer Z-plus-R responsiveness (unpublished
data). Therefore, it appears that Z-plus-R-induced activation of
the BMRF1 promoter occurs through a different mechanism than
the Z-plus-c-myb effect.
It is likely that cell-specific factors contribute to Z-plus-R
cooperative activation of the BMRF1 promoter since this
cooperation does not occur in epithelial cells. There are a number
of ways that cellular factors may contribute to Z-plus-R
cooperative activation. One possibility is that there is a BMRF 1
promoter-specific inhibitor in lymphoid cells which prevents
activation by one (or both) of these EBV transactivators. The
binding of one of these EBV transactivator proteins to the BMRF1
promoter might disrupt binding of this hypothetical inhibitor and
thereby increase the efficiency of the other EBV transactivator.
Our finding that the AP- 1 and -106 mutants have increased
constitutive activity in Jurkat cells (more so than in HeLa cells,
data not shown) suggests that lymphoid-specific inhibitors may
bind near these regions. A second possibility is that there is a
transactivator-specific inhibitor which inhibits either Z or R
function in lymphoid cells and that this effect is abolished when
both R and Z are bound to the BMRF1 promoter. In addition,
a cellular factor present in HeLa cells but not in Jurkat cells may
enhance cooperative interaction between the Z homodimers bound
at the -106 and AP-1 sites.
At present complete understanding of the mechanism of
transactivation by Z-plus-R is not possible. However, we have
made a number of observations regarding Z-plus-R cooperative
activation. As described above, we found that both Z and R
binding sites are required for cooperative activation by Z-plus-
R. To date a direct protein-protein interaction between R and
Z has not been demonstrated despite investigation by a number
of laboratories (including our own). The lack of direct
protein -protein interaction and the lack of Z-plus-R cooperative
activation of the BMRF1 promoter in epithelial cells suggest that
Z-plus-R activation is dependent in some fashion on cell specific
factors. These observations, along with observations made by
other investigators (21), currently suggest that Z-plus-R
cooperative activation is dependent upon 1) direct binding by R
and Z to responsive promoter elements and 2) interactions
between R, Z and cellular transcription factors.
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